ethyl (E)-4-[2-(5,6,7,8-tetrahydro-5,5-dimethyl-8-oxo-2-naphthalenyl)ethenyl]-benzoate | 188889-20-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: ethyl (E)-4-[2-(5,6,7,8-tetrahydro-5,5-dimethyl-8-oxo-2-naphthalenyl)ethenyl]-benzoate
• 英文别名: ethyl (E)-4[2-(5,6-dihydro-5,5-dimethyl-naphthalen-8(7H)-one-2-yl)ethenyl]-benzoate；ethyl(E)-4-[2-(5,6-dihydro-5,5-dimethylnaphthalen-8(7H)-one-2-yl)ethenyl]-benzoate；ethyl 4-[(E)-2-(5,5-dimethyl-8-oxo-6,7-dihydronaphthalen-2-yl)ethenyl]benzoate
• CAS: 188889-20-5
• 化学式: C₂₃H₂₄O₃
• 分子量: 348.442
• InChiKey: PADLSOOHRSUZBH-AATRIKPKSA-N

物化性质

• 沸点：
  514.7±50.0 °C(Predicted)
• 密度：
  1.128±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl (E)-4-[2-(5,6,7,8-tetrahydro-5,5-dimethyl-8-oxo-2-naphthalenyl)ethenyl]-benzoate 在 盐酸羟胺 、 sodium acetate 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 ethyl (E)-4-[2-(5,5-dimethyl-5,6-dihydro-8(7H)-anti-(oxime)-naphthalene-2-yl)ethenyl]-benzoate
  参考文献：
  名称：

  O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity

  摘要：

  式中符号的含义如申请中所述，具有类视黄醇或类视黄醇拮抗剂样的生物活性。

  公开号：

  US06344561B2
• 作为产物：
  描述：

  4-乙烯基-苯甲酸乙基酯 、 7-溴-4,4-二甲基-1-四氢萘酮 在 palladium diacetate 、 三(邻甲基苯基)磷 作用下， 以 三乙胺 为溶剂， 反应 2.5h， 生成 ethyl (E)-4-[2-(5,6,7,8-tetrahydro-5,5-dimethyl-8-oxo-2-naphthalenyl)ethenyl]-benzoate
  参考文献：
  名称：

  O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity

  摘要：

  式中符号的含义如申请中所述，具有类视黄醇或类视黄醇拮抗剂样的生物活性。

  公开号：

  US06344561B2

文献信息

• Oxime substituted tetrahydronaphthalene derivatives having retinoid
  申请人：Allergan

  公开号：US05723666A1

  公开（公告）日：1998-03-03

  Compounds of the formula ##STR1## have retinoid-like or retinoid antagonist-like biological activity.

  ##STR1##的化合物具有类似视黄醇或视黄醇拮抗剂的生物活性。
• Synthesis and use of retinoid compounds having negative hormone and/or
  申请人：Allergan Sales, Inc.

  公开号：US05877207A1

  公开（公告）日：1999-03-02

  Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

  芳基取代和芳基和（3-氧代-1-丙烯基）取代的苯并吡喃、苯并硫吡喃、1,2-二氢喹啉和5,6-二氢萘衍生物具有视黄醇负性激素和/或拮抗剂样生物活性。所发明的RAR拮抗剂可用于哺乳动物，包括人类，以防止或减轻RAR激动剂对结合受体位点的作用。具体而言，RAR激动剂可与视黄醇药物一起给予或联合给予，以防止或减轻视黄醇或维生素A或维生素A前体引起的毒性或副作用。视黄醇负性激素可用于增强其他视黄醇和核受体激动剂的活性。例如，名为AGN 193109的视黄醇负性激素在体外转录激活实验中有效增加了其他视黄醇和类固醇激素的效力。此外，转录激活实验可用于识别具有负性激素活性的化合物。这些实验基于负性激素调节具有构成转录激活子结构域的嵌合视黄醇受体活性的能力。
• Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
  申请人：——

  公开号：US20020173631A1

  公开（公告）日：2002-11-21

  Compounds of the formula 1 where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.

  式子1中的符号所描述的化合物具有类视黄醇或类视黄醇拮抗剂类似的生物活性。
• Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
  申请人：——

  公开号：US20030219832A1

  公开（公告）日：2003-11-27

  Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

  取代芳基和取代芳基和（3-氧代-1-丙烯基）基苯并吡喃、苯并硫吡喃、1,2-二氢喹啉和5,6-二氢萘衍生物具有视黄醛受体负性激素和/或拮抗剂样的生物活性。发明的RAR拮抗剂可用于哺乳动物，包括人类，以防止或减少RAR激动剂对结合受体位点的作用。具体而言，RAR激动剂与视黄醇药物一起使用或联合使用，以防止或缓解视黄醇或维生素A或维生素A前体引起的毒性或副作用。视黄醛负性激素可用于增强其他视黄醇和核受体激动剂的活性。例如，名为AGN 193109的视黄醛负性激素在体外转录激活测定中有效地增加了其他视黄醇和类固醇激素的效力。此外，转录激活测定可用于鉴定具有负性激素活性的化合物。这些测定基于负性激素降调节嵌合视黄醛受体活性的能力。
• O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
  申请人：——

  公开号：US20030078440A1

  公开（公告）日：2003-04-24

  Compounds of the formula 1 where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.

  符号具有申请中所描述的含义的公式1的化合物具有类视黄醇或类视黄醇拮抗剂样的生物活性。